Trial: 201711182

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer



Principal Investigator

Reimers, Melissa

Disease Site

Other Urinary; Urinary Bladder

Learn more about this study at: